Pfizer gets LITFULO FDA approval for severe alopecia areata
Pfizer has announced that the US Food and Drug Administration (FDA) has granted approval to LITFULO (ritlecitinib) as a once-daily oral treatment for individuals aged 12 and older with severe alopecia areata. LITFULO is the first and only FDA-approved therapy for adolescents (12+) with severe alopecia areata. The recommended dose for LITFULO is 50 mg. […]